18/12/2020 - Press release
The journal Neurology has just published the most complete and exhaustive study to date on the survival rate and sequelae of patients who suffer a ruptured brain aneurysm, a disease known as subarachnoid haemorrhage. The work was carried out by doctors at Hospital del Mar (from the Neurology, Neurosurgery, Intensive Medicine, Interventional Neuroradiology, Radiology and Anaesthesia and Resuscitation services) and researchers from the Hospital del Mar Medical Research Institute (IMIM). The results show that the strategy implemented in Catalonia to cover emergency care for this condition produces results comparable to those of the most advanced centres in the world. The data analysed corresponds to 311 patients with aneurysmal subarachnoid haemorrhage treated at Hospital del Mar over the last 12 years. The short-term mortality rate is between 8.7% (one week after treatment, during the hospitalisation period), and 18.4% (after three months). One year after the vascular event, this figure reaches 22.9% and, five years later, 29%. Only 7% of the patients who survived after five years presented disabling sequelae. According to several studies, deaths from this pathology around the world are between 11% and 27.5% in hospital and over 30% after three months.
Més informació "Only 7% of patients treated for a brain aneurysm suffer long-term sequelae"
2/12/2020 - Press release
The article published in the journal World Psychiatry and endorsed by the informal scientific network of the United Nations Office on Drugs and Crime (UNODC) and the World Health Organisation (WHO), and including the United States National Institute of Drug Abuse (NIDA), validates and corroborates the approach to the dual diagnosis implemented at Hospital del Mar for patients being treated for addiction to a substance of abuse who, in addition, suffer another psychiatric pathology. Dual diagnosis is a major health problem that causes, according to the article, an increased number of emergencies in healthcare centres, as well as more psychiatric hospitalisations, a higher risk of relapse into drug use and premature death, including suicide. This has individual and social repercussions, as well as consequences for healthcare systems, and means that a multidisciplinary and comprehensive approach is required. Nevertheless, as the authors of the paper point out, there is a generalised lack of preparedness to deal with this situation.
01/12/2020 - Press release
The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a grant for 1,970,520 Euro from the Spanish National Innovation Agency to develop an innovative treatment for fragile X syndrome (FXS), the most common form of hereditary intellectual disability. The grant comes from the 2019 "Collaboration Challenges" call for projects of the National R&D&I Programme geared towards societal challenges. The call received 420 applications, 158 of which will be funded.
17/11/2020 - Press release
Nutritional parameters such as body mass index and tests including albumin and total protein levels quantified prior to lung cancer surgery in patients with chronic obstructive pulmonary disease (COPD) predict their 10 year survival, regardless of tumour-related factors and/or chest surgery. This is reflected in the work of researchers from the CIBER of Respiratory Diseases (CIBERES) and doctors and researchers from the Hospital del Mar Pneumology Service and the Hospital del Mar Medical Research Institute research group on muscle wasting and cachexia in chronic respiratory diseases and lung cancer (IMIM-Hospital del Mar), published in the journal of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) Archivos de Bronconeumología. The researchers studied the nutritional status of lung cancer and COPD patients who required surgery and the relationship of this with post-operative survival. To do this, they analysed the nutritional status of 125 patients from Hospital del Mar, 87 of whom had COPD and lung cancer and 38 of whom had cancer but no COPD, before they underwent chest surgery. The patients were monitored for 10 years in order to study their differential survival rates according to the presence or absence of COPD.
29/10/2020 - Press release
The Hospital del Mar Medical Research Institute (IMIM), together with the INCLIVA Health Research Institute, from Hospital Clínic in Valencia, and the Vall d'Hebron Institute of Oncology, have obtained funding from the Spanish Association Against Cancer (AECC) for their project entitled Factors derived from the tumoral microenvironment in localised colon cancer: clinical impact and therapeutic implications. Dr. Clara Montagut, head of the Gastrointestinal Cancer Unit in the Medical Oncology Service at Hospital del Mar, coordinator of the Clinical and Translational Research Group on new therapies and biomarkers in colon and rectal cancer at the Hospital del Mar Medical Research Institute (IMIM) and a participant in the study, points out that "The goal of this research is to identify markers that will help us determine whether the cancer will re-emerge in a patient who has undergone colon cancer surgery. This is extremely important for people who have colon cancer, since at present we are unable to predict whether the tumour will reappear or not after surgery.
27/10/2020 - Press release
A team of researchers from the Germans Trias i Pujol Hospital and Research Institute (IGTP) and the Hospital del Mar Medical Research Institute (IMIM) has shown that regularly consuming foods rich in omega-3 fatty acids, from both animal and vegetable origins, strengthens the heart's membranes and helps improve the prognosis in the event of a myocardial infarction. To arrive at these conclusions, they used data from 950 patients. The omega-3 levels in the blood of these individuals were determined when they were admitted to hospital to be treated for the heart attack. This measurement indicates, very accurately, how much of these fats the patients had eaten in the weeks prior to the sampling, in other words, before the heart attack. The patients were monitored for three years after being discharged, and the researchers observed that having high levels of omega-3 in the blood at the time of the infarction, which had been consumed in the weeks leading up to the heart attack, was associated with a lower risk of complications. The results of the study have just been published in the prestigious Journal of the American College of Cardiology.
19/10/2020 - Press release
Last Friday, the FERO Foundation announced the winners of the 19th FERO Grants and the winner of the 2nd FERO-Mango Breast Cancer Research Project. The grants, worth €80,000 each, are intended to help young researchers develop their translational cancer research projects over a two-year period. "It is expected that 277,394 people will be diagnosed with cancer before the end of 2020. We cannot allow the pandemic scenario in which we find ourselves to detract from the treatment and survival opportunities of the thousands of patients who are currently struggling with cancer. That is why at FERO we are doing everything we can to ensure that COVID-19 affects doctors and patients as little as possible, and that resources continue to reach researchers and centres. One way of achieving this is by continuing to support projects through our grants", explains Sol Daurella, president of the institution.
15/10/2020 - Press release
They believe that the treatment currently used in many cases, based solely on short-acting bronchodilators like the well-known Ventolin, may increase the risk of severe asthma attacks. This is revealed by a study published in the journal Archivos de Bronconeumología. They advocate the use of inhaled corticoids, which is also the treatment recommended by the international Global Initiative for Asthma (GINA). Asthma is increasingly prevalent and affects 5-10% of the general population. Unfortunately, the decline in associated mortality has slowed in recent years. In the current context, characterised by the COVID-19 epidemic, there is no evidence that suffering asthma implies a more severe form of COVID-19.
14/10/2020 - Press release
Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO with the aim to consolidate its transition from a software business to a key player in the biotech sector. Dr Boyer joins Chemotargets from Swedish drug development company Klaria, where he has been CEO/CSO since 2015 and will continue as a member of the Board of Directors and as a scientific advisor. Prior to joining Klaria, he was Chief Scientist at AstraZeneca (Sweden), with global responsibility for molecular and investigational toxicology across the company, and a member of the company's senior management team. Prior to AstraZeneca, Dr. Boyer was a senior scientist at Pfizer Central Research in the US.
Més informació "Dr. Scott Boyer joins Chemotargets as new CEO"
08/10/2020 - Press release
Doing 150 minutes of moderate-intensity physical activity (fast walking or dancing, for example) or 75 minutes of vigorous activity (running or other sports) a week, as recommended by the World Health Organisation (WHO), reduces your mortality risk by 16%. At the same time, cardiovascular mortality risk drops by 27% and cardiovascular event risk falls by 12%. This is highlighted in a study published by the Revista Española de Cardiología led by doctors from Hospital del Mar and researchers from the Hospital del Mar Medical Research Institute (IMIM), the University of Vic-Central Catalonia (UVic- UCC), and the CIBERCV and CIBERESP. The work also reveals that doing three to five times more physical activity than the recommended amount maximises the benefit.
Més informació "Following physical activity recommendations can reduce mortality risk by 16%"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
